Literature DB >> 29225541

Should You Use ACTH or Vigabatrin for Infantile Spasms? Or Why Not Use Both Together?

Prakash Kotagal.   

Abstract

Entities:  

Year:  2017        PMID： 29225541      PMCID： PMC5716497          DOI： 10.5698/1535-7597.17.5.285

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  9 in total

1.  The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

2.  Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  C Y Go; M T Mackay; S K Weiss; D Stephens; T Adams-Webber; S Ashwal; O C Snead
Journal:  Neurology       Date:  2012-06-12       Impact factor: 9.910

3.  Optimizing Care With a Standardized Management Protocol for Patients With Infantile Spasms.

Authors:  Erin M Fedak; Anup D Patel; Geoffrey L Heyer; Eric G Wood; John R Mytinger
Journal:  J Child Neurol       Date:  2014-12-22       Impact factor: 1.987

4.  Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.

Authors:  Finbar J K O'Callaghan; Stuart W Edwards; Fabienne Dietrich Alber; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Marcus Likeman; Andrew L Lux; Mark Mackay; Andrew A Mallick; Richard W Newton; Melinda Nolan; Ronit Pressler; Dietz Rating; Bernhard Schmitt; Christopher M Verity; John P Osborne
Journal:  Lancet Neurol       Date:  2016-11-10       Impact factor: 44.182

5.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet Neurol       Date:  2005-11       Impact factor: 44.182

6.  Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort.

Authors:  Kelly G Knupp; Erin Leister; Jason Coryell; Katherine C Nickels; Nicole Ryan; Elizabeth Juarez-Colunga; William D Gaillard; John R Mytinger; Anne T Berg; John Millichap; Douglas R Nordli; Sucheta Joshi; Renée A Shellhaas; Tobias Loddenkemper; Dennis Dlugos; Elaine Wirrell; Joseph Sullivan; Adam L Hartman; Eric H Kossoff; Zachary M Grinspan; Lorie Hamikawa
Journal:  Epilepsia       Date:  2016-09-12       Impact factor: 5.864

Review 7.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

8.  Response to treatment in a prospective national infantile spasms cohort.

Authors:  Kelly G Knupp; Jason Coryell; Katherine C Nickels; Nicole Ryan; Erin Leister; Tobias Loddenkemper; Zachary Grinspan; Adam L Hartman; Eric H Kossoff; William D Gaillard; John R Mytinger; Sucheta Joshi; Renée A Shellhaas; Joseph Sullivan; Dennis Dlugos; Lorie Hamikawa; Anne T Berg; John Millichap; Douglas R Nordli; Elaine Wirrell
Journal:  Ann Neurol       Date:  2016-02-13       Impact factor: 10.422

Review 9.  Corticosteroids for the treatment of infantile spasms: a systematic review.

Authors:  Ravindra Arya; Shlomo Shinnar; Tracy A Glauser
Journal:  J Child Neurol       Date:  2012-08-01       Impact factor: 1.987
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.